On March 15, Salarius Pharmaceuticals Inc. (SLRX) finally rebounded in the after-hours following its continued downfall after its latest earnings. The company had declared its 2021 financial results on March 10.
During the regular trading session, the stock suffered a loss of 7.00% while the volume of shares exchanged remained above the average. The stock closed the session in the red at a price of $0.3441 per share. Following this, the stock rebounded in the after-hours to add a good 10.43%. Hence, SLRX stock was trading at a value of $0.3800 per share in the after-hours on Tuesday.
The clinical-stage oncology company, Salarius Pharmaceuticals Inc. is based in Houston, TX. Currently, its 45.21 million outstanding shares trade at a market capitalization of $16.73 million.
What Happened with SLRX?
On March 10, the company reported its financial results for the fourth quarter and full-year 2021. Following this, the stock entered a downtrend which continued till March 15’s regular session. After plunging down for over 10.39% in the past five days, the stock finally rebounded and entered green in the after-hours on Tuesday. Since there is no recent news from the company, the downfall seems to be the reason for the comeback. In addition to external factors, it seems the low price was taken as a good buying opportunity by the investors.
Presently, SLRX stock stands at a year-to-date loss of 30.57% while it subtracted a huge value of 77.06% in the past year.
2021 Financial Results
For Q4 2021, the company reported a net loss of 44.1 million against $1.8 million in the year-ago period. Therefore, the net loss per basic and diluted share was $0.09 and $0.10 in Q4 2021 and 2020, respectively.
Moreover, the fiscal 2021 net loss was $12.8 million against $7.4 million for fiscal 2020. Thus, the net loss per basic and diluted share was $0.31 and $0.50 for fiscal 2021 and 2020, respectively.
Furthermore, SLRX ended 2021 with cash, cash equivalents, and restricted cash of $29.2 million. This compares to $11.1 million at the end of fiscal 2020. The company expects the cash position to be enough to fund its operations through 2023.
SLRX’s Recent Participations
Recently, the company participated in the Diamond Equity Research Emerging Growth Invitational 2022 Virtual Conference. SLRX’s CEO David Arthur, presented at the conference on February 24, 2022.
Previously, Mr. Arthur also presented at the 2022 BIO CEO & Investor Conference which took place from February 14-17, 2022.